This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carter, J. J. Articles by Galloway, D. A. Search for Related Content PubMed PubMed Citation Articles by Carter, J. J. Articles by Galloway, D. A.

Human Papillomavirus 16 and 18 L1 Serology Compared across Anogenital Cancer Sites¹

Programs in Cancer Biology [J. J. C., K. S., G. C. W., P. P., J. K. M., D. A. G.] and Epidemiology [M. M. M., S. M. S., K. L. C-H., J. R. D.], Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024; Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington [M. M. M., S. M. S., J. R. D.]; and Departments of Pathology [P. P., J. K. M.] and Microbiology [D. A. G.], School of Medicine, University of Washington, Seattle, Washington 98195-0005

Human papillomavirus (HPV) DNA has been detected in the great majority of cancers of the uterine cervix and anus, whereas the association of HPV DNA with cancer at other anogenital sites has produced less consistent results. This study was designed to compare HPV exposure among anogenital cancer cases and matched controls. Cases (1782) of anogenital cancer diagnosed in the Seattle area from 1978 to 1998 were identified and interviewed. Their responses were compared with those of 2383 age- and sex-matched controls. Blood was drawn at interview from both cases and controls and tested for antibodies to HPV-16 and HPV-18. Tissue blocks were tested for HPV DNA for 649 cases. Serum antibodies to HPV-16 were associated with in situ and invasive cancer at all sites among men and women with the exception of in situ penile cancer. Anti-HPV-18 antibodies were associated with cancers at all sites among women. The increased risk of cancer associated with HPV-16 seropositivity ranged from odds ratio = 1.8 (95% confidence interval, 1.4–2.5) for adenocarcinoma of the cervix to odds ratio = 5.9 (95% confidence interval, 3.4–10.3) for anal cancer in men. Associations between seroprevalence and cancers were stronger when analyses were restricted to HPV-16- or HPV-18 DNA-positive cases. HPV DNA was detected in >80% of cancers from all sites tested. HPV-16 DNA was the type most frequently detected at all sites (range, 40.9–82.2%). HPV-18 DNA was detected in 44.7% of adenocarcinomas of the cervix but detected much less often (2.6–18.1%) at other sites. These findings support an important role for HPV infection in anogenital cancer at all sites. Differences in the proportion of seropositives among HPV-16 DNA-positive cases by site suggest either that the immune response varies by site or that cancer development may lead to changes in antibody responses in a site-specific fashion.

This article has been cited by other articles:

				J. J. Carter, K. G. Paulson, G. C. Wipf, D. Miranda, M. M. Madeleine, L. G. Johnson, B. D. Lemos, S. Lee, A. H. Warcola, J. G. Iyer, et al. Association of Merkel Cell Polyomavirus-Specific Antibodies With Merkel Cell Carcinoma J Natl Cancer Inst, November 4, 2009; 101(21): 1510 - 1522. [Abstract] [Full Text] [PDF]

				C Miralles-Guri, L Bruni, A L Cubilla, X Castellsague, F X Bosch, and S de Sanjose Human papillomavirus prevalence and type distribution in penile carcinoma J. Clin. Pathol., October 1, 2009; 62(10): 870 - 878. [Abstract] [Full Text] [PDF]

				C M Vajdic, M T van Leeuwen, F Jin, G Prestage, G Medley, R J Hillman, M P Stevens, L P Botes, I Zablotska, S N Tabrizi, et al. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men Sex Transm Inf, September 1, 2009; 85(5): 330 - 335. [Abstract] [Full Text] [PDF]

				R. A. Katzenellenbogen, P. Vliet-Gregg, M. Xu, and D. A. Galloway NFX1-123 Increases hTERT Expression and Telomerase Activity Posttranscriptionally in Human Papillomavirus Type 16 E6 Keratinocytes J. Virol., July 1, 2009; 83(13): 6446 - 6456. [Abstract] [Full Text] [PDF]

				S. M. Garland, R. P. Insinga, H. L. Sings, R. M. Haupt, and E. A. Joura Human Papillomavirus Infections and Vulvar Disease Development Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1777 - 1784. [Abstract] [Full Text] [PDF]

				Z. R. Edelstein, M. M. Madeleine, J. P. Hughes, L. G. Johnson, S. M. Schwartz, D. A. Galloway, J. J. Carter, and L. A. Koutsky Age of Diagnosis of Squamous Cell Cervical Carcinoma and Early Sexual Experience Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1070 - 1076. [Abstract] [Full Text] [PDF]

				D. J. Hutchinson and K. C. Klein Human papillomavirus disease and vaccines Am. J. Health Syst. Pharm., November 15, 2008; 65(22): 2105 - 2112. [Abstract] [Full Text] [PDF]

				M. Jit, Y. H. Choi, and W J. Edmunds Economic evaluation of human papillomavirus vaccination in the United Kingdom BMJ, July 17, 2008; 337(jul17_2): a769 - a769. [Abstract] [Full Text] [PDF]

				R. P. Insinga, K.-L. Liaw, L. G. Johnson, and M. M. Madeleine A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1611 - 1622. [Abstract] [Full Text] [PDF]

				S. K. Hussain, M. M. Madeleine, L. G. Johnson, Q. Du, M. Malkki, H.-W. Wilkerson, F. M. Farin, J. J. Carter, D. A. Galloway, J. R. Daling, et al. Cervical and Vulvar Cancer Risk in Relation to the Joint Effects of Cigarette Smoking and Genetic Variation in Interleukin 2 Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1790 - 1799. [Abstract] [Full Text] [PDF]

				M. M. Madeleine, L. G. Johnson, A. G. Smith, J. A. Hansen, B. B. Nisperos, S. Li, L.-P. Zhao, J. R. Daling, S. M. Schwartz, and D. A. Galloway Comprehensive Analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 Loci and Squamous Cell Cervical Cancer Risk Cancer Res., May 1, 2008; 68(9): 3532 - 3539. [Abstract] [Full Text] [PDF]

				D. A.M. Heideman, T. Waterboer, M. Pawlita, P. Delis-van Diemen, I. Nindl, J. A. Leijte, J. M.G. Bonfrer, S. Horenblas, C. J.L.M. Meijer, and P. J.F. Snijders Human Papillomavirus-16 Is the Predominant Type Etiologically Involved in Penile Squamous Cell Carcinoma J. Clin. Oncol., October 10, 2007; 25(29): 4550 - 4556. [Abstract] [Full Text] [PDF]

				R. P. Insinga, E. J. Dasbach, E. H. Elbasha, K.-L. Liaw, and E. Barr Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 709 - 715. [Abstract] [Full Text] [PDF]

				J. J. Carter, G. C. Wipf, M. M. Madeleine, S. M. Schwartz, L. A. Koutsky, and D. A. Galloway Identification of human papillomavirus type 16 l1 surface loops required for neutralization by human sera. J. Virol., May 1, 2006; 80(10): 4664 - 4672. [Abstract] [Full Text] [PDF]

				D. Dias, J. Van Doren, S. Schlottmann, S. Kelly, D. Puchalski, W. Ruiz, P. Boerckel, J. Kessler, J. M. Antonello, T. Green, et al. Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18 Clin. Vaccine Immunol., August 1, 2005; 12(8): 959 - 969. [Abstract] [Full Text] [PDF]

				J. Webber and D. Fromm Photodynamic Therapy for Carcinoma In Situ of the Anus Arch Surg, March 1, 2004; 139(3): 259 - 261. [Abstract] [Full Text] [PDF]

				J. J. Carter, M. M. Madeleine, G. C. Wipf, R. L. Garcea, P. A. Pipkin, P. D. Minor, and D. A. Galloway Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans J Natl Cancer Inst, October 15, 2003; 95(20): 1522 - 1530. [Abstract] [Full Text] [PDF]

				K. A. Rosenblatt, J. J. Carter, L. M. Iwasaki, D. A. Galloway, and J. L. Stanford Serologic Evidence of Human Papillomavirus 16 and 18 Infections and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 763 - 768. [Abstract] [Full Text] [PDF]

				M. L. Gillison and K. V. Shah Chapter 9: Role of Mucosal Human Papillomavirus in Nongenital Cancers J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 57 - 65. [Abstract] [Full Text] [PDF]

				T. Iftner and L. L. Villa Chapter 12: Human Papillomavirus Technologies J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 80 - 88. [Abstract] [Full Text] [PDF]

				L. F. Voigt, T. D. Koepsell, and J. R. Daling Characteristics of Telephone Survey Respondents According to Willingness to Participate Am. J. Epidemiol., January 1, 2003; 157(1): 66 - 73. [Abstract] [Full Text] [PDF]